Journal Mobile Options
Table of Contents
Vol. 22, No. 6, 2001
Issue release date: November–December 2001 (December 2001)
Section title: Research Article
Tumor Biol 2001;22:348–366
(DOI:10.1159/000050638)

The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences

O’Brien T.J.a · Beard J.B.a · Underwood L.J.a · Dennis R.A.a · Santin A.D.a · York L.b
aDepartment of Obstetrics and Gynecology and bDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Ark., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact service@karger.com


Article / Publication Details

First-Page Preview
Abstract of Research Article

Published online: 12/24/2001
Issue release date: November–December 2001 (December 2001)

Number of Print Pages: 19
Number of Figures: 10
Number of Tables: 1

ISSN: 1010-4283 (Print)
eISSN: 1423-0380 (Online)

For additional information: http://www.karger.com/TBI

Abstract

CA 125 has long presented problems to both clinicians and investigators because there was no definitive information on its structure and function. Here, we describe our work on cloning the CA 125 gene with the anticipation that such information will provide the basis for understanding its structure and its physiologic role in both normal and malignant tissues. The CA 125 protein core is composed of a short cytoplasmic tail, a transmembrane domain and an extraordinarily large glycosylated extracellular structure. This structure is dominated by a repeat domain composed of 156 amino acid repeat units which encompass the epitope binding sites. The molecule also includes an amino terminal domain of serine/threonine-rich sequences which would account for most of the O-glycosylation known to be present in CA 125. CA 125 is an unusually large transmembrane glycoprotein. Its release from the surface of the cell is most probably dependent on cytoplasmic phosphorylation followed by proteolytic cleavage. The extracellular domain is characterized by a large number of repeat units (probably 60+) which encompass an interactive disulfide bridged cysteine-loop and the site of OC125 and M11 binding. Sequencing the gene provides us with the ability to initiate the quest to understand the biological function of CA 125.

© 2001 S. Karger AG, Basel


  

Author Contacts

Timothy J. O’Brien
University of Arkansas for Medical Sciences
4301 West Markham, Slot 718
Little Rock, AR 72205 (USA)
Tel. +1 501 686 6696, Fax +1 501 686 8501, E-Mail obrientimothyj@uams.edu

  

Article Information

Received: Received: August 11, 2001
Accepted after revision: September 13, 2001
Number of Print Pages : 19
Number of Figures : 10, Number of Tables : 1, Number of References : 31

  

Publication Details

Tumor Biology (Tumor Markers and Translational Cancer Research)
Founded 1980 as ‘Oncodevelopmental Biology and Medicine’ by the ISOBM, continued 1984–1986 as ‘Tumour Biology’
The Journal of the International Society for Oncodevelopmental Biology and Medicine (ISOBM)

Vol. 22, No. 6, Year 2001 (Cover Date: November-December 2001 (Released December 2001))

Journal Editor: T. Stigbrand, Umeå; Managing Editor: P.D. Rye, Oslo
ISSN: 1010–4283 (print), 1423–0380 (Online)

For additional information: http://www.karger.com/journals/tbi


Article / Publication Details

First-Page Preview
Abstract of Research Article

Published online: 12/24/2001
Issue release date: November–December 2001 (December 2001)

Number of Print Pages: 19
Number of Figures: 10
Number of Tables: 1

ISSN: 1010-4283 (Print)
eISSN: 1423-0380 (Online)

For additional information: http://www.karger.com/TBI


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.